Tobe S W, Siu L L, Jamal S A, Skorecki K L, Murphy G F, Warner E
Division of Nephrology, Sunnybrook Health Science Centre, University of Toronto, Canada.
Cancer Chemother Pharmacol. 1995;35(3):188-90. doi: 10.1007/BF00686546.
Vinblastine and erythromycin are among the most commonly used chemotherapeutic and antimicrobial agents, respectively. No interaction between the two has ever been reported. Towards the end of a phase I study of vinblastine plus oral cyclosporin (to reverse multidrug resistance), three patients also received erythromycin to raise their cyclosporin levels. All developed severe toxicity consistent with a much higher vinblastine dose than was actually given. This apparent potentiation of vinblastine toxicity has not been previously described.